These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 25582496)

  • 1. PD-L1 expression in small cell neuroendocrine carcinomas.
    Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R
    Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
    J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
    Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
    JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
    Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
    Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
    Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
    Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
    Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
    Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.
    Hassan SS; Akram M; King EC; Dockrell HM; Cliff JM
    PLoS One; 2015; 10(9):e0137646. PubMed ID: 26359860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
    He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
    J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
    Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
    Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.